Chad Cowan - 02 Feb 2026 Form 4 Insider Report for Century Therapeutics, Inc. (IPSC)

Role: Chief Scientific Officer
Signature: /s/ Douglas Carr, Attorney-in-Fact
Issuer symbol: IPSC
Transactions as of: 02 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 04 Feb 2026, 16:15:01 UTC
Previous filing: 06 Jan 2026
Next filing: 13 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Cowan Chad	Chief Scientific Officer	C/O CENTURY THERAPEUTICS, INC., 25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA	/s/ Douglas Carr, Attorney-in-Fact	04 Feb 2026	0002039294

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IPSC	Common Stock	Award	$0	+135,000	+13%	$0.000000	1,178,476	02 Feb 2026	Direct	F1
holding	IPSC	Common Stock						10,697	02 Feb 2026	By Trust	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IPSC	Stock Option (right to buy)	Award	$0	+265,000		$0.000000	265,000	02 Feb 2026	Common Stock	265,000	$1.84	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
F2	Shares held by the Cowan Investment Nominee Trust. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
F3	The option vests 25% on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date.